Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lipocine (LPCN) Operating Margin (2018 - 2025)

Lipocine (LPCN) has disclosed Operating Margin for 8 consecutive years, with 2933.51% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Margin changed N/A year-over-year to 2933.51%, compared with a TTM value of 119.21% through Sep 2025, down 4748.0%, and an annual FY2024 reading of 0.02%, up 62899.0% over the prior year.
  • Operating Margin was 2933.51% for Q3 2025 at Lipocine, down from 386.03% in the prior quarter.
  • Across five years, Operating Margin topped out at 5207.01% in Q2 2021 and bottomed at 7889.86% in Q1 2023.
  • Average Operating Margin over 5 years is 983.71%, with a median of 305.81% recorded in 2023.
  • The sharpest move saw Operating Margin tumbled -591251bps in 2022, then soared 793216bps in 2024.
  • Year by year, Operating Margin stood at 59.09% in 2021, then crashed by -1294bps to 705.51% in 2022, then surged by 213bps to 795.1% in 2023, then tumbled by -90bps to 77.4% in 2024, then crashed by -3890bps to 2933.51% in 2025.
  • Business Quant data shows Operating Margin for LPCN at 2933.51% in Q3 2025, 386.03% in Q2 2025, and 2226.82% in Q1 2025.